|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TLR4 single nucleotide polymorphisms may play an important protective role in the development of hepatocellular carcinoma.
|
21559380 |
2011 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gut sterilization restricted to late stages of hepatocarcinogenesis reduced HCC, suggesting that the intestinal microbiota and TLR4 represent therapeutic targets for HCC prevention in advanced liver disease.
|
22516259 |
2012 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The TLR4 rs2148356 T allele is associated with a reduced risk of HCC and could slow down its clinical progression in HCV-induced chronic liver disease.
|
22286521 |
2012 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry confirmed increased expression of TLR2 and TLR4 in hepatitis and cirrhosis and maintained expression in hepatocarcinoma.
|
22330637 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human hepatocellular carcinoma cells (HepG2 and HuH7) were incubated in media including 2% bovine serum albumin and 250 to 1000 μM palmitate for 24 h. Signaling mediated by TLR4 was blocked by a TLR4 decoy peptide or small interfering RNA knockdown of TLR4.
|
23465595 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that the activated TLR4/NANOG oncogenic pathway is linked to suppression of cytostatic TGF-β signaling and could potentially serve as a therapeutic target for HCV-related HCC.
|
23921128 |
2013 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TLR4 was overexpressed in HCC cell lines and in human HCC tissues, where it correlated with Ki-67 expression.
|
23828139 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the aim of this review is to present the recent data regarding the important roles of TLR4 in HBV recognition and regulation of immune responses against this virus, and also its roles in the pathogenesis of cirrhosis and HCC as complications of prolonged hepatitis B infections.
|
25014492 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the expression of TLR4 was detected in the peripheral blood mononucleated cell of hepatocellular carcinoma (HCC) patients, suggesting that mRNA and protein levels of TLR4 might be associated with SNP rs1057317.
|
25179842 |
2014 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additionally, high expression of TLR4 in HCC tissues was strongly associated with both early recurrence and poor survivals in patients.
|
25511737 |
2015 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of TLR4 were examined in a panel of HCC cell lines (HepG2, SMMC7721, Huh7, HepG2.2.15 and Hep3B).
|
26514586 |
2015 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TLR4-mediated BCL6 upregulation was crucial for PD-1(hi) B-cell induction by HCC environmental factors, and that effect was abolished by IL4-elicited STAT6 phosphorylation.
|
26928313 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
TLR4 on macrophages contributes to the development of steatohepatitis-related HCC in mice.
|
27022031 |
2016 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The SNPs associated with HCC risk in patients with cirrhosis and CHB were rs11536889 in TLR4 and rs2853744 in SPP1.
|
27391584 |
2016 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In multivariate logistic regression analysis, Milan criteria, microvascular invasion and donor TLR4 rs1927914 genotype were confirmed to be independent risk factors for HCC recurrence.
|
29221801 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The positive rates of TLR4 and β-catenin were higher in HCC tissues compared with normal tissues.
|
28578348 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TLR4 is an innate immunity receptor which plays a pathogenic role during chronic inflammation and can induce HCC in human.
|
28472619 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The LPS-TLR4 (Toll-like receptor 4) pathway in HSC is responsible for HCC angiogenesis.
|
29036356 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Toll-like receptor 4 (TLR4) appears to play an important role in the development and progression of hepatocellular carcinoma (HCC), but it is unclear whether single-nucleotide polymorphisms (SNPs) in the TLR4 gene influence HCC.
|
28945461 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stimulation of Toll-like receptor 4 (TLR4) by bacterial lipopolysaccharide (LPS) initiates inflammation and promotes development of hepatocellular carcinoma and other liver diseases.
|
29085012 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the effects of TLR4 on M2-polarized macrophages in hepatocellular carcinoma (HCC) are unknown.
|
29338742 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the current results suggested that the TLR4/MyD88 signaling pathway is involved in HCC cell proliferation and metastasis via regulation of the IL-23/IL-17A axis; thus, the TLR4/IL-23/IL-17A pathway may represent a novel therapeutic target in HCC.
|
29928340 |
2018 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The inhibition of TLR4, VEGFR2 and TRAIL expression in HCC and non-tumor liver tissue may lessen the severity of RILDs and improve survival outcomes in the future.
|
29928336 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Modulation of the gut-liver axis and the LPS-Tlr4 response by RIPC, gut sterilization, and Tlr4 antagonism represents a potential therapeutic target to prevent I/R lesions, and to alleviate HCC recurrence after liver transplantation and resection.
|
29331341 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HBsAg/β2GPI activates the NF‑κB pathway via the TLR4/MyD88/IκBα axis in hepatocellular carcinoma.
|
29916535 |
2018 |